Holen Sie sich die Stockscreener-App
2.20
0.00%
0.00
Handel nachbörslich:
2.11
-0.09
-4.09%
Imunon Inc Aktie (IMNN) Neueste Nachrichten
Imunon Inc. (IMNN) Nudges Higher Amid Tight Trading RangeBackspread Trade - Newser
IMNN Stock Price, Quote & Chart | IMUNON INC (NASDAQ:IMNN) - ChartMill
Imunon (IMNN.US) is scheduled to release its earnings report before the market opens on March 31. - Moomoo
Imunon (IMNN) Up +0.71% — 3 Reasons the Rally Could Continue 2026-05-21Ichimoku TK Cross - Newser
Imunon Earnings Call Balances Breakthroughs and Cash Strain - TipRanks
Why Is Imunon, Inc. (CLSN) Stock Up Today? - Meyka
Why Is Imunon, Inc. (CLSN) Stock Down Today? - Meyka
Imunon (IMNN) Slides -3.61% as Selling Pressure Mounts 2026-05-18Skew Index - Newser
Earnings call transcript: Imunon Inc. misses Q1 2026 EPS forecast, stock dips - Investing.com
Imunon targets OVATION 3 last patient enrollment in Q1 2029 while outlining preferred-share financing options - MSN
Armistice Capital (IMNN) discloses 396,718 shares, 9.99% stake - Stock Titan
Q1 2026 Imunon Inc Earnings Call Transcript - GuruFocus
IMNN: On Track to Have 80 Patients Enrolled in Phase 3 OVATION 3 Trial by 1Q27 - Yahoo Finance
UK Housing Market Gloom Persists, RICS Survey Signals Continued WeaknessSocial Trade Signals - newser.com
Imunon (IMNN) Declines -3.00% Amid Market Weakness 2026-05-13AI Signals - newser.com
Imunon | 10-Q: Q1 2026 Earnings Report - Moomoo
Imunon, Inc. (NASDAQ:IMNN) Q1 2026 Earnings Call Transcript - Insider Monkey
Imunon Q1 2026 Earnings Preview - MSN
Earnings call transcript: Imunon Q1 2026 highlights clinical trial progress By Investing.com - Investing.com India
IMNN: IMUNON Progresses in Clinical Trials with Strong Financial Management - GuruFocus
Imunon’s Earnings Call Balances Survival Gains and Risks - TipRanks
Imunon Inc (IMNN) Q1 2026 Earnings Call Highlights: Promising Clinical Progress Amidst Funding ... By GuruFocus - Investing.com Canada
Imunon Inc (IMNN) Q1 2026 Earnings Call Highlights: Promising Cl - GuruFocus
IMNN's Enrollment in Phase 3 Trial Exceeds Expectations - GuruFocus
A. G. P. Maintains Imunon(IMNN.US) With Buy Rating, Maintains Target Price $12 - Moomoo
IMUNON, INC. Q1 2026 SEC 10-Q Filing: Financial Statements, Risk Factors, and Management Discussion - Minichart
How Should Investors Value Imunon (IMNN) After Q1 2026 Earnings? - GuruFocus
Imunon Releases Q1 2026 Financial Results - AlphaStreet
IMUNON Reports Promising Phase 2 Survival Data and Advances Phase 3 OVATION 3 Trial for Ovarian Cancer in Q1 2026 Financial Results Update - Minichart
Earnings call transcript: Imunon Q1 2026 highlights clinical trial progress - Investing.com
Imunon (IMNN) Q1 2026 Earnings Transcript - AOL.com
IMNN: OVATION 3 enrollment outpaces forecasts as IMNN-001 shows strong survival benefit in ovarian cancer - TradingView
Imunon Reports Q1 2026 Results: Full Earnings Call Transcript - Benzinga
Imunon: FDA Has Reviewed and Is Aligned With Phase 3 Protocol, Confirms Path to BLA Filing - Moomoo
[10-Q] Imunon, Inc. Quarterly Earnings Report - Stock Titan
Imunon, Inc. 1Q 2026: Net loss $(4.25M), EPS $(0.84) — 10-Q Summary - TradingView
IMUNON ($IMNN) Releases Q1 2026 Earnings - Quiver Quantitative
IMUNON Reports First Quarter 2026 Financial Results and Provides Business Update - The Manila Times
Imunon Q1 net loss widens as R&D spending rises - TradingView
IMUNON (NASDAQ: IMNN) posts Q1 2026 loss while IMNN-001 shows strong survival data - Stock Titan
Imunon (IMNN.US) is scheduled to release its earnings report before the market opens on May 12. - Moomoo
Number of shareholders of Imunon, Inc. – NASDAQ:IMNN - TradingView
MSN Money - MSN
May 12 webcast to cover IMUNON's Q1 results, Phase 3 ovarian cancer update - Stock Titan
IMUNON to Hold First Quarter 2026 Financial Results and Business Update Conference Call on Tuesday, May 12, 2026 - Yahoo Finance
Imunon to discuss Q1 2026 financials and Phase 3 trial progress for ovarian cancer immunotherapy on May 12. - Pluang
0.98%
0.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):